News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
813,126 Results
Type
Article (75266)
Company Profile (643)
Press Release (737217)
Section
Business (226584)
Career Advice (3717)
Deals (39177)
Drug Delivery (128)
Drug Development (89089)
Employer Resources (198)
FDA (17780)
Job Trends (17072)
News (386341)
Policy (38684)
Tag
2024 BioCapital Digital (20)
2024 BioForest Digital (16)
2024 BioForest Standard (1)
2024 BioMidwest Digital (14)
2024 BioMidwest Standard (2)
2024 Bio NC Digital (19)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (20)
2024 Biotech Beach Digital (15)
2024 Biotech Beach Standard (9)
2024 Genetown Digital (10)
2024 Genetown Standard (12)
2024 Lone Star Bio Digital (17)
2024 Pharm Country Digital (13)
2024 Pharm Country Standard (7)
2025 BioForest Digital (6)
2025 Lone Star Bio Digital (9)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (1)
Academia (2990)
Academic (1)
Accelerated approval (3)
Adcomms (29)
Allergies (85)
Alliances (55812)
ALS (91)
Alzheimer's disease (1463)
Antibody-drug conjugate (ADC) (139)
Approvals (17743)
Artificial intelligence (266)
Autoimmune disease (19)
Automation (14)
Bankruptcy (401)
Best Places to Work (12632)
BIOSECURE Act (21)
Biosimilars (114)
Biotechnology (439)
Bladder cancer (63)
Brain cancer (29)
Breast cancer (266)
Cancer (2099)
Cardiovascular disease (172)
Career advice (3162)
Career pathing (33)
CAR-T (160)
Cell therapy (443)
Cervical cancer (19)
Clinical research (71632)
Collaboration (823)
Compensation (459)
Complete response letters (29)
COVID-19 (2855)
CRISPR (42)
C-suite (223)
Cystic fibrosis (105)
Data (1925)
Decentralized trials (2)
Denatured (42)
Depression (49)
Diabetes (267)
Diagnostics (6871)
Digital health (18)
Diversity (9)
Diversity, equity & inclusion (48)
Drug discovery (120)
Drug pricing (122)
Drug shortages (33)
Duchenne muscular dystrophy (91)
Earnings (92795)
Editorial (39)
Employer branding (25)
Employer resources (167)
Events (127808)
Executive appointments (668)
FDA (18922)
Featured Employer (65)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (737)
Gene editing (108)
Generative AI (26)
Gene therapy (315)
GLP-1 (813)
Government (5064)
Grass and pollen (4)
Guidances (48)
Healthcare (20856)
Huntington's disease (24)
IgA nephropathy (25)
Immunology and inflammation (125)
Indications (27)
Infectious disease (2999)
Inflammatory bowel disease (145)
Inflation Reduction Act (11)
Influenza (51)
Intellectual property (87)
Interviews (727)
IPO (17695)
IRA (51)
Job creations (4942)
Job search strategy (2592)
Kidney cancer (10)
Labor market (38)
Layoffs (531)
Leadership (20)
Legal (9898)
Liver cancer (76)
Lung cancer (306)
Lymphoma (133)
Machine learning (2)
Management (65)
Manufacturing (297)
MASH (66)
Medical device (14547)
Medtech (14552)
Mergers & acquisitions (21940)
Metabolic disorders (715)
Multiple sclerosis (74)
NASH (23)
Neurodegenerative disease (97)
Neuropsychiatric disorders (31)
Neuroscience (1982)
NextGen: Class of 2025 (7638)
Non-profit (5075)
Northern California (2430)
Now hiring (38)
Obesity (391)
Opinion (270)
Ovarian cancer (73)
Pain (87)
Pancreatic cancer (78)
Parkinson's disease (138)
Partnered (19)
Patents (214)
Patient recruitment (96)
Peanut (50)
People (63605)
Pharmaceutical (132)
Pharmacy benefit managers (21)
Phase I (22123)
Phase II (31233)
Phase III (23569)
Pipeline (972)
Podcasts (119)
Policy (133)
Postmarket research (3273)
Preclinical (9731)
Press Release (72)
Prostate cancer (95)
Psychedelics (38)
Radiopharmaceuticals (266)
Rare diseases (396)
Real estate (7122)
Recruiting (75)
Regulatory (25840)
Reports (57)
Research institute (2651)
Resumes & cover letters (580)
Rett syndrome (3)
RNA editing (2)
RSV (45)
Schizophrenia (73)
Series A (132)
Series B (83)
Service/supplier (26)
Sickle cell disease (55)
Southern California (2113)
Special edition (18)
Spinal muscular atrophy (165)
Sponsored (33)
Startups (4185)
State (2)
Stomach cancer (15)
Supply chain (66)
The Weekly (74)
United States (22169)
Vaccines (766)
Venture capitalists (39)
Webinars (13)
Weight loss (289)
Women's health (38)
Worklife (18)
Date
Today (118)
Last 7 days (514)
Last 30 days (2965)
Last 365 days (36174)
2025 (8094)
2024 (37896)
2023 (42567)
2022 (53926)
2021 (58722)
2020 (57663)
2019 (51304)
2018 (39083)
2017 (36822)
2016 (37718)
2015 (43723)
2014 (38363)
2013 (34395)
2012 (36328)
2011 (36369)
2010 (35789)
Location
Africa (1198)
Alabama (56)
Alaska (7)
Arizona (235)
Arkansas (14)
Asia (48444)
Australia (8324)
California (5682)
Canada (1892)
China (495)
Colorado (258)
Connecticut (279)
Delaware (131)
Europe (109309)
Florida (825)
Georgia (202)
Hawaii (1)
Idaho (63)
Illinois (561)
India (26)
Indiana (311)
Iowa (10)
Japan (138)
Kansas (106)
Kentucky (27)
Louisiana (11)
Maine (68)
Maryland (889)
Massachusetts (4409)
Michigan (232)
Minnesota (393)
Mississippi (2)
Missouri (85)
Montana (31)
Nebraska (26)
Nevada (58)
New Hampshire (68)
New Jersey (1624)
New Mexico (31)
New York (1625)
North Carolina (1055)
North Dakota (8)
Northern California (2430)
Ohio (204)
Oklahoma (15)
Oregon (45)
Pennsylvania (1270)
Puerto Rico (10)
Rhode Island (28)
South America (1565)
South Carolina (19)
South Dakota (1)
Southern California (2113)
Tennessee (95)
Texas (849)
Utah (172)
Virginia (149)
Washington D.C. (65)
Washington State (549)
West Virginia (3)
Wisconsin (59)
813,126 Results for "jiangsu hengrui medicine co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
March 25, 2025
·
5 min read
Business
Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd’s Commercial Launch of VIVJOA® (Oteseconazole) Capsules for the Treatment of Severe Vulvovaginal Candidiasis (VVC) in China
Mycovia Pharmaceuticals, Inc. today announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd (“Hengrui”) has commercially launched VIVJOA® (oteseconazole) in China, making available an innovative oral azole antifungal indicated for the treatment of severe vulvovaginal candidiasis (VVC).
February 7, 2024
·
7 min read
Bio NC
Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd’s Approval of Oteseconazole Capsules for the Treatment of Severe Vulvovaginal Candidiasis (VVC) in China
Mycovia Pharmaceuticals, Inc. today announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd (“Hengrui”) received approval in June from the National Medical Products Administration for Oteseconazole Capsules, an azole antifungal, indicated for the treatment of severe vulvovaginal candidiasis (VVC).
August 21, 2023
·
7 min read
Press Releases
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Report Positive Topline Data from 8 mg Dose of Phase 2 Obesity Trial of GLP-1/GIP Receptor Dual Agonist HRS9531
January 13, 2025
·
5 min read
Business
Mycovia Pharmaceuticals, Inc. Announces Publication of Partner Jiangsu Hengrui Pharmaceuticals’ Phase 3 Clinical Study Evaluating the Efficacy and Safety of VIVJOA® (Oteseconazole)
Mycovia Pharmaceuticals, Inc. today announced that its partner Jiangsu Hengrui Pharmaceuticals Co., Ltd (“Hengrui”) has published its phase 3 study evaluating the efficacy and safety of VIVJOA® (oteseconazole) capsules versus fluconazole in the treatment of severe vulvovaginal candidiasis (VVC) in Chinese women in the journal Antimicrobial Agents and Chemotherapy.
January 31, 2024
·
7 min read
Drug Development
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
HUTCHMED Limited announces the initiation of a Phase II/III trial to evaluate the efficacy of a combination of the HUTCHMED drug candidate surufatinib, the Jiangsu Hengrui Pharmaceuticals Co., Ltd PD-1 antibody camrelizumab, nab-paclitaxel and gemcitabine as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma in China.
May 13, 2024
·
8 min read
Pharm Country
Jiangsu Hengrui Pharma and Elevar Therapeutics Announce Global Commercialization Licensing Agreement for PD-1 Inhibitor Camrelizumab in Combination with Rivoceranib for uHCC
Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Elevar Therapeutics, Inc. announced a global licensing agreement that grants Elevar rights to commercialize and develop Hengrui Pharma’s anti-PD-1 antibody camrelizumab in combination with rivoceranib for unresectable hepatocellular carcinoma worldwide, excluding Greater China Region and Korea.
October 17, 2023
·
5 min read
Pharm Country
Elevar Therapeutics and Jiangsu Hengrui Pharma Announce Global Commercialization Licensing Agreement for PD-1 Inhibitor Camrelizumab in Combination with Rivoceranib for uHCC
Elevar Therapeutics, Inc. and Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced a global licensing agreement that grants Elevar rights to commercialize and develop Hengrui Pharma’s anti-PD-1 antibody camrelizumab in combination with rivoceranib for unresectable hepatocellular carcinoma worldwide, excluding Greater China Region and Korea.
October 17, 2023
·
6 min read
Merck KGaA, Darmstadt, Germany, Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate
Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd.
October 30, 2023
·
5 min read
Hengrui Pharma Partners with Merck KGaA, Darmstadt, Germany, to Advance Innovative Cancer Therapies
Jiangsu Hengrui Pharmaceuticals Co., Ltd announced a licensing agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company, for its next-generation potent and selective PARP1 inhibitor, HRS-1167.
October 30, 2023
·
4 min read
1 of 81,313
Next
